As a scientific discipline, toxicology exists at the nexus of human health, regulatory science, and basic research. This interdisciplinary nature is what drew me to this field as a young undergraduate while taking a course called “humans and their environment” and is the reason I still love my career path today.
At Boston Scientific, I lead a team responsible for the biological evaluation in support of new products. Similarly, this evaluation is repeated for commercialized products each time there is a change to materials, design, or processing over the entire lifecycle of the device. The data we generate play a significant role in the regulatory approval of our products and our continued compliance requires us to develop long range strategies to ensure we stay ahead of global regulatory expectations in this space.
I received my PhD in pharmacology and toxicology from Dartmouth College in 2003 and went on to complete post-doctoral fellowship at the Chemical Industry Institute of Toxicology (CIIT). Since 2006 I’ve worked in the medical device industry and have designed and managed preclinical safety programs to support stent and balloon-based drug delivery programs, led technology development projects to support the biological evaluation of combination medical device products, supported contract pharmaceutical R&D and manufacturing operations, and led teams of toxicologists and biocompatibility specialists for two major medical device manufacturers. Throughout my career I have consistently delivered business critical results with the vision, determination, and skills to develop actionable strategies and tactics for success and have demonstrated excellent collaborative skills to achieve business goals across a highly matrixed environment.
A Diplomate of the American Board of Toxicology (DABT) since 2012, I served on the ABT Board of Directors from 2019-2023 including executive committee roles of Secretary (2020-2021), Vice President (2021-2022), and President (2022-2023). Maintaining the standard of practice, ensuring it remains current with the rapid advances in the field of toxicology, and recognizing those toxicologists who demonstrate competence against those standards are all vitally important and I’m incredibly proud of the work the board accomplished during this time period.